Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.

Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.

Glioblastoma multiforme (GBM), the most common form of brain cancer with an average survival of less than 12 months, is a highly aggressive and fatal disease characterized by survival of glioma cells following initial treatment, invasion through the brain parenchyma and destruction of normal brain t...

Full description

Bibliographic Details
Main Authors: Xiao-Yuan Liu, Li Zhang, Jianping Wu, Lei Zhou, Yi-Jie Ren, Wei-Qiong Yang, Zi-Jun Ming, Bo Chen, Jianrong Wang, Yi Zhang, Jin-Ming Yang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3841121?pdf=render

Internet

http://europepmc.org/articles/PMC3841121?pdf=render

Similar Items